HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Induction of hepatic tumors in rats by senkirkine and symphytine.

Abstract
The carcinogenicity of the pyrrolizidine alkaloids senkirkine and symphytine was studied in male inbred ACI rats. Animals were divided into 3 groups: Group I received ip injections of freshly prepared senkirkine at a dose of 10% of the median lethal dose (LD50) twice weekly for 4 weeks and then once a week for 52 weeks. Group II received ip injections of symphytine at a dose of 10% of the LD50 by the same injection schedule as in group I. The control group was given ip injections of a 0.9% NaCl solution following the same injection schedule as in experimental groups. All group I rats survived for more than 290 days after the start of injections, and 9 of 20 rats developed liver cell adenoma. All group II animals survived for more than 330 days after the start of injections. Of 20 rats, 4 had liver tumors, 3 had hemangioendothelial sarcomas, and 1 had liver cell adenoma. The hemangioendothelial sarcomas showed metastasis in the lungs of 2 rats. The control group had no liver tumors.
AuthorsI Hirono, M Haga, M Fujii, S Matsuura, N Matsubara, M Nakayama, T Furuya, M Hikichi, H Takanashi, E Uchida, S Hosaka, I Ueno
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 63 Issue 2 Pg. 469-72 (Aug 1979) ISSN: 0027-8874 [Print] United States
PMID287835 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Pyrrolizidine Alkaloids
  • symphytine
  • senkirkine
Topics
  • Animals
  • Hemangioendothelioma (chemically induced, pathology)
  • Liver Neoplasms (chemically induced, pathology)
  • Liver Neoplasms, Experimental (chemically induced, pathology)
  • Male
  • Neoplasms, Experimental (chemically induced)
  • Pyrrolizidine Alkaloids (toxicity)
  • Rats
  • Rats, Inbred ACI
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: